Sponsors, CROs, and regulators commonly organise clinical development by therapeutic area, so the area a programme sits in shapes its patient population, the expertise it needs, and much of its operational risk. This article explains what therapeutic areas and profiles the main areas in clinical research. It then sets out where trial activity is concentrated now, the novel modalities and operational pressures affecting trials, and the sponsor and geography shifts behind recent growth.
Therapeutic areas within clinical research represent specific medical fields dedicated to understanding diseases, developing treatments, and conducting rigorous scientific investigations. By categorising research into these areas, such as infectious disease, cardiology, vaccine & virology, and immunology, experts can efficiently focus their expertise and resources to develop more targeted and effective treatments to address specific health challenges. These areas guide the design and implementation of clinical trials aimed at advancing medical knowledge and improving patient care.
Regulatory guidance can also differ by area, so sponsors typically plan regulatory strategy with that area’s conventions in mind. There’s no single, fixed list of therapeutic areas. Classification depends on who is grouping the research and why. The FDA’s list of therapeutic areas covered by its paediatric. Written Requests (formal FDA requests for studies in children), dated 31 December 2019, uses categories and treats psychiatry, renal disease, and rheumatology as areas in their own right.
As an industry that is continuously evolving, certain therapeutic areas in clinical research stand out due to their significant impact on global health and the opportunities they present for innovation. Understanding these key areas is essential for industry professionals aiming to navigate the complexities of drug development and deliver effective treatments to patients worldwide. Below, we explore some of the most common therapeutic areas that are at the forefront of clinical research today.
Oncology remains a primary focus in clinical research due to the global prevalence of cancer and the urgent need for more effective treatments. Advances in molecular biology and genetics have been key drivers for personalised medicine, allowing for therapies tailored to individual patient profiles. Immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, are changing the face of cancer treatment by harnessing the body's immune system to fight cancer cells. Ongoing research is also exploring combination therapies to improve efficacy and overcome resistance mechanisms.
Trials are complex because of the heterogeneity of tumour types and subtypes, genetic mutations, and mechanisms of drug resistance. Many targeted therapies also depend on companion diagnostics (tests that identify which patients are likely to benefit) and biomarkers, which adds that aforementioned regulatory complexity.
Haematology encompasses disorders related to blood and bone marrow, including anaemia, haemophilia, and leukaemia. Clinical research in this area is critical for developing therapies that can manage or cure these conditions. Gene therapy has shown promise, particularly in treating hereditary blood disorders like sickle cell disease and beta-thalassemia. Stem cell research and advancements in bone marrow transplantation techniques are also contributing to better patient outcomes. Treatments such as bone marrow transplantation and CAR-T cell therapy require specialised technology and carry significant risks, so trials need careful safety oversight.
Although individually uncommon, rare diseases collectively affect millions of people worldwide. The challenges in researching these conditions include small patient populations and limited understanding of disease mechanisms. Patients are often spread across many countries and established clinical endpoints are frequently lacking, so trials typically need novel designs. However, regulatory incentives like orphan drug designations are encouraging investment and innovation. Clinical trials are increasingly focusing on gene therapies, enzyme replacement therapies, and other targeted approaches to address the underlying causes of rare diseases.
Dermatological conditions, such as psoriasis, eczema, and skin cancers, significantly impact patients' quality of life. Clinical research is advancing our understanding of the skin's immune responses and the genetic factors contributing to these conditions. Biologic therapies are providing new treatment options for chronic skin diseases by targeting specific pathways involved in inflammation. Additionally, non-invasive diagnostic tools and advanced topical formulations are enhancing patient care.
The global burden of infectious diseases continues to drive research in developing new antibiotics, antivirals, and vaccines. Antimicrobial resistance poses a significant threat, necessitating the discovery of novel compounds and treatment strategies. Clinical trials are also focusing on neglected tropical diseases and emerging pathogens to improve global health outcomes.
Cardiovascular diseases are the leading cause of death globally. Research in cardiology, including heart disease, stroke, and hypertension, are vital for developing interventions that can prevent, manage, or reverse these conditions. Clinical studies are exploring innovative treatments such as gene editing, regenerative therapies using stem cells, and advanced medical devices like bioresorbable stents. Personalised medicine approaches are also being investigated to tailor treatments based on genetic risk factors.
Trials are complicated by causes that combine genetics, lifestyle, and comorbid conditions. Conditions such as heart failure and arrhythmias also make patient stratification and long-term outcome assessment difficult.
Neurological disorders present complex challenges due to the intricate nature of the nervous system. Clinical research is focused on uncovering disease pathophysiology to develop disease-modifying therapies. Advances in neuroimaging and biomarkers are enhancing early diagnosis and monitoring of disease progression. Novel therapeutic approaches, such as monoclonal antibodies and neuroprotective agents, are under investigation.
Conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are among the most complex to study. The blood-brain barrier, which restricts what passes from the bloodstream into the brain, limits drug delivery, and disease mechanisms are often not fully understood. Trials also face difficult recruitment, endpoint selection, and slow disease progression.
The field of vaccinology and virology is essential for preventing infectious diseases and managing public health crises. Clinical research is expanding into developing vaccines for a range of viral infections, including those for which no vaccines currently exist. mRNA vaccine technology, used at scale during the COVID-19 pandemic, offers rapid development timelines and adaptability. Research is also focusing on universal vaccines that can provide broad protection against multiple strains of viruses.
Gastrointestinal disorders and diseases of the digestive system like inflammatory bowel disease (Crohn's disease and ulcerative colitis), irritable bowel syndrome, and gastrointestinal cancers are significant areas of clinical research. Studies are examining the role of the gut microbiome in health and disease, leading to potential microbiome-based therapies. Advances in endoscopic techniques and minimally invasive procedures are improving diagnostic and treatment options for patients.
Immunology is foundational to understanding a wide array of diseases, from autoimmune disorders to allergies and cancer. Clinical studies research the complexities of the immune system to develop therapies that can modulate immune responses precisely. Biologics and small molecule inhibitors targeting specific immune pathways are being developed to treat conditions like rheumatoid arthritis, lupus, inflammatory bowel disease, and asthma. Modulating immune responses without compromising the wider immune system is a significant challenge, and variability between patients and unpredictable disease courses add complexity.
Endocrinology concentrates on hormonal disorders and the endocrine system, which governs hormonal balance and regulates vital bodily functions. Clinical research in this area addresses conditions like diabetes mellitus, thyroid disorders, hormonal imbalances, and osteoporosis. Advances include the development of novel insulin therapies and continuous glucose monitoring systems for better diabetes management.
Ophthalmology deals with the study of eye health and the treatment of visual disorders. Clinical research is crucial for developing therapies for conditions such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts. Innovations include anti-VEGF therapies that have enhanced treatment for retinal diseases, advanced surgical techniques for cataract removal, and minimally invasive procedures for glaucoma management. Ongoing studies focus on early detection methods and gene therapies for inherited eye conditions.
Two types of data help answer this, and they measure different things. All-time trial counts show where research has built up over decades, while recent trials show where sponsors are committing new programmes.
Oncology has the largest body of registered trials by a clear margin. Mental health, neurological, metabolic, and cardiovascular conditions follow, with infections, respiratory, and digestive diseases close behind. Exact shares depend on how a dataset groups conditions, so figures from different registries and databases shouldn’t be compared directly.
Oncology still accounts for the largest share of industry-sponsored trial starts, and enrolment in oncology trials still typically takes considerably longer than in other areas.
Obesity is another fast-growing area. Trials have multiplied over the past decade, driven by the success of incretin-based therapies (drugs that mimic gut hormones involved in blood sugar control and appetite). Growth is now shifting towards mid- and late-stage programmes, which suggests the pipeline is maturing.
Immunology and neurology also continue to grow. In immunology, Janus kinase (JAK) inhibitors, which block enzymes involved in inflammatory signalling, still account for a large share of activity, but therapies acting on newer targets such as CD19, TSLP and TL1A are broadening the field. Neurology trial activity keeps rising despite long-standing development challenges, particularly in Alzheimer’s disease, depression and Parkinson’s disease.
A small number of areas, led by oncology and obesity, account for a disproportionate share of new activity, and that concentration shapes competition for sites, patients and specialist expertise.
Many of the newest developments in clinical research are treatment approaches, or modalities, rather than new disease areas, and most can be applied across several therapeutic areas. In oncology, novel modalities such as antibody-drug conjugates, radiopharmaceuticals, cell and gene therapies and multi-specific antibodies now make up a far larger share of new trials than they did a decade ago.
Regenerative medicine focuses on repairing or replacing damaged tissues and organs using stem cells and bioengineered tissues. Stem cell therapies are being explored for a range of conditions, including spinal cord injuries, heart disease, and neurodegenerative disorders. The ability to regenerate damaged tissues offers hope for treatments that restore function rather than just manage symptoms. Transplantation and regenerative therapies are complex to study because of immune rejection, the need to keep transplanted tissue viable and ethical questions around stem cell use.
Research into the gut microbiome is exploring how manipulating the gut microbiota can treat conditions like inflammatory bowel disease, obesity, and even mental health disorders. Faecal microbiota transplantation and probiotics are examples of microbiome-based interventions under investigation.
RNA-based therapies, including mRNA and siRNA, have gained significant attention, especially with the success of mRNA vaccines for COVID-19. These therapies can instruct cells to produce specific proteins or silence disease-causing genes. Clinical research is expanding into treatments for cancer, rare genetic diseases, and infectious diseases using RNA platforms.
While immunotherapy has optimised cancer treatment, new research is applying immunomodulation strategies to other diseases such as autoimmune disorders, infectious diseases, and even neurodegenerative conditions. Therapies targeting immune checkpoints, cytokines, and cellular therapies are being explored to modulate immune responses effectively.
Epigenetics involves changes in gene expression without altering the DNA sequence. Epigenetic therapies aim to reverse abnormal gene expression patterns associated with diseases like cancer and neurological disorders. Drugs targeting DNA methylation and histone modification enzymes are in clinical trials, offering a new avenue for treatment.
Nanomedicine utilises nanoparticles for diagnosis, monitoring, control, prevention, and treatment of diseases. Nanoparticles can deliver drugs directly to targeted cells, reducing side effects and improving efficacy. Applications in oncology, infectious diseases, and regenerative medicine are being actively researched.
Bispecific antibodies are engineered proteins that can bind to two different antigens simultaneously. They are now an established part of oncology development. They work by redirecting immune cells to target specific disease cells more effectively. Trials are also investigating their use in autoimmune conditions.
Senolytics are drugs that selectively induce death of senescent cells, which contribute to aging and age-related diseases. Clinical research is investigating the potential of senolytics in treating conditions such as osteoarthritis, pulmonary fibrosis, and cardiovascular diseases, aiming to improve health span and longevity.
Metabolomics studies the unique chemical fingerprints left by metabolic processes. New therapies target metabolic pathways to treat diseases like cancer, metabolic syndrome, and rare metabolic disorders. By modulating metabolism, these therapies offer new strategies for disease intervention.
Building on the success of CAR-T cell therapies in oncology, researchers are exploring other forms of adoptive cell therapies, including CAR-NK (natural killer) cells and TILs (tumour-infiltrating lymphocytes). These therapies aim to enhance the body's immune response to fight cancer and are being investigated for their safety and efficacy.
11. Gene Therapy and Gene Editing
Gene therapy modifies genes within a patient’s cells to address the cause of disease at the molecular level, while gene-editing technologies such as CRISPR-Cas9 make precise changes to DNA. Targets include genetic conditions such as cystic fibrosis, sickle cell anaemia, Duchenne muscular dystrophy and haemophilia.
Gene therapy also crosses therapeutic boundaries. Trials are investigating it for neovascular age-related macular degeneration (nAMD), an eye condition that leads to vision loss, and as a way to modify the immune system to target cancer cells. Delivery mechanisms, long-term safety and ethical questions all add complexity.
12. Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) attach a cytotoxic drug to an antibody that binds a target on cancer cells, so the drug is delivered more selectively.
13. Radiopharmaceutical Therapies
Radiopharmaceutical therapies (RPTs) deliver a radioactive isotope to diseased cells, typically by linking it to a molecule that binds a target on tumour cells. They bring specific supply and site requirements.
Despite the exciting advancements in therapeutic research, several challenges remain:
Lack of Biomarkers and Endpoints
Difficulty in identifying reliable biomarkers and clinical endpoints complicates trial design and the assessment of therapeutic efficacy.
Data Management and Analysis
Managing and analysing large volumes of complex data requires validated systems and sophisticated analytical methods to ensure accuracy and validity, and adopting AI and machine learning adds further demand on expertise and infrastructure.
Safety Monitoring and Regulatory Compliance
Continuous safety monitoring, including early identification of adverse effects, is needed to protect participants and avoid costly failures, and it demands significant resources.
Complex Trial Designs
Designing trials that account for genetic and environmental variations involves intricate protocols and can limit eligible participant pools.
Patient Recruitment and Retention
Strict inclusion criteria, geographical limitations, and patient reluctance due to potential risks hinder enrolment and retention in clinical trials. Real-world evidence, drawn from sources such as health records and registries, is one of several approaches sponsors use to ease this burden.
Globalisation Challenges
Multi-national trials have to work across different healthcare systems, languages, cultural expectations, and regulatory requirements, which takes careful planning and resources.
As we look ahead, clinical research is set to evolve further with the integration of new technologies and scientific discoveries, fundamentally changing how we prevent, diagnose, and treat diseases. Below are some of the key technologies driving change:
Advancements in Medical Devices
Research and development in medical devices continue to innovate across a broad spectrum of tools designed to enhance diagnosis, treatment, and patient monitoring. Advanced imaging systems that provide detailed internal views of the body are enhancing the precision and efficiency of healthcare delivery. Additionally, robotic-assisted surgical devices are improving surgical outcomes by allowing for minimally invasive procedures with greater accuracy.
Digital Health Integration
The integration of digital health technologies is becoming increasingly prevalent in clinical research and patient care. Wearable devices and telemedicine platforms now play an essential role in real-time health monitoring, providing continuous data that can be invaluable for clinical trials and ongoing patient management. These technologies enable remote monitoring of vital signs, adherence to treatment protocols, and early detection of potential health issues, thereby improving overall patient outcomes and engagement.
Digital Therapeutics
Digital therapeutics represent a new class of medicine that delivers evidence-based therapeutic interventions through high-quality software programs. Utilising mobile applications and wearable technology, these interventions can manage or treat a wide array of medical conditions. For instance, they offer cognitive behavioural therapy for mental health disorders, aid in chronic disease management like diabetes, and support medication adherence programs. The seamless integration of these tools into patients' daily lives provides real-time support and personalised strategies, enhancing the effectiveness of treatments. Healthcare providers benefit from data-driven insights, allowing for timely adjustments to therapy plans.
Artificial Intelligence and Machine Learning in Drug Development
The incorporation of artificial intelligence (AI) and machine learning (ML) is changing drug discovery and clinical trial design. AI algorithms analyse vast datasets to identify potential drug candidates, predict drug responses, and optimise trial protocols with greater accuracy and speed than traditional methods. This accelerates the development of new therapies across various therapeutic areas by enabling researchers to focus on the most promising compounds and streamline the clinical trial process.
Emerging biopharma companies, the smaller developers that sit outside large pharma, now sponsor the majority of new clinical trials, and their share has grown steadily in recent years. They lead most Phase I trials globally, while large pharmaceutical companies remain more prominent in Phase III, where scale, capital and regulatory experience matter most.
Pharmaceutical and biotechnology companies are increasingly outsourcing their R&D efforts to specialised research organisations, such as biometric CROs. This strategic shift allows companies to use external expertise, access advanced technologies, and accelerate the discovery and development of new therapeutics without the substantial investment required for in-house capabilities.
Trial geography is also changing. The United States and China together account for a large share of trial activity. China leads in Phase I activity, driven largely by domestic single-country trials, while the United States leads in Phase II and III. Europe’s share of trial starts has declined in relative terms over recent years.
In parallel to the uplift in R&D outsourcing, the global increase in chronic diseases such as diabetes, cardiovascular disorders, and metabolic syndromes is a significant driver of the therapeutic research market. Factors like an aging population, sedentary lifestyles, and environmental influences contribute to the growing prevalence of these conditions. As a result, there is an urgent demand for new and more effective therapies to manage and treat chronic illnesses.
Therapeutic areas give clinical research its basic structure, but activity within and across them continues to shift. For sponsors, the practical effects include longer enrolment, more demanding site and manufacturing requirements, and changes in who sponsors trial sand where they take place. Planning around the specific demands of a therapeutic area, and of the modality within it, it is a growing part of keeping a programme on schedule.
At Quanticate, we specialise in transforming clinical data into actionable insights that drive medical innovation, with particular expertise in complex trials and large datasets. As a leading global Biometric Contract Research Organisation (CRO), we offer comprehensive data-focused services across a wide array of therapeutic experiences including Oncology CRO, Vaccine & Virology CRO, Rare Disease CRO, Infectious Diseases CRO, Dermatology CRO, Neurology CRO, Immunology CRO, Cardiology CRO, Endocrinology CRO, Ophthalmology CRO, and more.
For over 30 years we have collaborated with pharmaceutical companies, biotech firms, and healthcare organisations to deliver biostatistics, statistical programming, biostatistical consultancy, clinical data management, pharmacovigilance, and medical writing services that support regulatory submissions and accelerate the development of effective treatments.
If you need support in one of these therapeutic areas, request a consultation below.